Literature DB >> 9267529

Dexmedetomidine, diazepam, and propranolol in the treatment of ethanol withdrawal symptoms in the rat.

P Riihioja1, P Jaatinen, H Oksanen, A Haapalinna, E Heinonen, A Hervonen.   

Abstract

In this study, the effects of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on ethanol withdrawal symptoms, were compared with those of diazepam and propranolol. The rats were given highly intoxicating doses of ethanol for 4 days. After the intoxication period, rats were divided into four equal groups: a dexmedetomidine-treated group (30 micrograms/kg, sc), a diazepam-treated group (2 mg/kg, sc), a propranolol-treated group (5 mg/kg, sc), and a control group with no medication. Medication was given in the withdrawal phase-2, 8, 14, and 20 hr after the onset of the withdrawal symptoms. The severity of the ethanol withdrawal symptoms (rigidity, tremor, irritability, and hypoactivity) was observed up to 33 hr after the onset of the ethanol withdrawal symptoms. Both dexmedetomidine and diazepam significantly relieved tremor compared with the control group. Diazepam reduced irritability significantly, compared with the control group. When measured as the sum score of the three most specific withdrawal signs (rigidity, tremor, and irritability), dexmedetomidine and diazepam significantly relieved the ethanol withdrawal reaction. Propranolol attenuated tremor, but was inefficient against other withdrawal symptoms. Dexmedetomidine may thus represent a new effective drug in the treatment of the ethanol withdrawal syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9267529

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  14 in total

1.  Current approaches to the recognition and treatment of alcohol withdrawal and delirium tremens: "old wine in new bottles" or "new wine in old bottles".

Authors:  Theodore A Stern; Anne F Gross; Thomas W Stern; Shamim H Nejad; Jose R Maldonado
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  Neurochemical mechanisms of alcohol withdrawal.

Authors:  Howard C Becker; Patrick J Mulholland
Journal:  Handb Clin Neurol       Date:  2014

3.  CRF1 Receptor-Dependent Increases in Irritability-Like Behavior During Abstinence from Chronic Intermittent Ethanol Vapor Exposure.

Authors:  Adam Kimbrough; Giordano de Guglielmo; Jenni Kononoff; Marsida Kallupi; Eric P Zorrilla; Olivier George
Journal:  Alcohol Clin Exp Res       Date:  2017-09-22       Impact factor: 3.455

Review 4.  Noradrenergic targets for the treatment of alcohol use disorder.

Authors:  Carolina L Haass-Koffler; Robert M Swift; Lorenzo Leggio
Journal:  Psychopharmacology (Berl)       Date:  2018-02-20       Impact factor: 4.530

Review 5.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

6.  Dexmedetomidine controls agitation and facilitates reliable, serial neurological examinations in a non-intubated patient with traumatic brain injury.

Authors:  Julin F Tang; Po-Liang Chen; Eric J Tang; Todd A May; Shirley I Stiver
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

7.  alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol.

Authors:  Brendan M Walker; Dennis D Rasmussen; Murray A Raskind; George F Koob
Journal:  Alcohol       Date:  2008-03       Impact factor: 2.405

Review 8.  Dexmedetomidine: a review of applications for cardiac surgery during perioperative period.

Authors:  Xiaoyu Zhang; Xuan Zhao; Yingwei Wang
Journal:  J Anesth       Date:  2014-06-10       Impact factor: 2.078

9.  Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: a retrospective case series.

Authors:  Jonas P DeMuro; David G Botros; Ela Wirkowski; Adel F Hanna
Journal:  J Anesth       Date:  2012-05-15       Impact factor: 2.078

Review 10.  Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research.

Authors:  Andrew J Muzyk; Suzanne Kerns; Scott Brudney; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.